Trials / Completed
CompletedNCT06683352
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 1,353 (actual)
- Sponsor
- BioNTech SE · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Investigational Influenza Vaccine | Investigational Influenza Vaccine |
| BIOLOGICAL | COVID-19 Vaccine | Pfizer-BioNTech COVID-19 Vaccine |
| COMBINATION_PRODUCT | Influenza and COVID Combination Vaccine | Combined investigational influenza and Pfizer-BioNTech COVID-19 Vaccine |
| BIOLOGICAL | Licensed Influenza Vaccine 1 | Licensed Influenza Vaccine 1 |
| BIOLOGICAL | Licensed Influenza Vaccine 2 | Licensed Influenza Vaccine 2 |
| OTHER | Placebo | Saline |
Timeline
- Start date
- 2024-11-11
- Primary completion
- 2025-07-15
- Completion
- 2025-07-15
- First posted
- 2024-11-12
- Last updated
- 2025-08-15
Locations
22 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06683352. Inclusion in this directory is not an endorsement.